What do systematic reviews say?

Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD

Summary of findings ‐ nebulisers for delivering colistin:… may leads to lower participant satisfaction or preference compared with AAD (low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.45 [0.35, 0.57]
  1 study · 259 participants
  Low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 10 participants
  Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Summary of findings ‐ nebulisers for delivering dornase alfa:… may leads to lower participant satisfaction or preference: compared with VMT (low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.48 [0.31, 0.76]
  1 study · 68 participants
  Low

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 8 participants
  Very low

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes participant satisfaction or preference Satisfaction scale compared with VMT and AAD (very low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  MD 2.7 [1.35, 4.05]
  1 study · 22 participants
  Very low